H umans have three canonical activating FcgRs (CD16, CD32A, and CD64) and one inhibitory receptor (CD32B). With the exception of CD64, these receptors are of low to moderate affinity, meaning that Fc multimers of the appropriate isotype are required for effective signaling (1) . Interestingly, B cells express only the inhibitory CD32B FcgR, which is thought to serve as a physiologic brake for Ab production (2) . Specifically, Ag complexed to both the BCR and Ab permits crosslinking of CD32B on the B cell surface, inhibiting B cell function via an ITIM-mediated signaling cascade (3, 4) . In the absence of Agspecific Ab, Fc-bearing immune aggregates can induce CD32B-mediated B cell apoptosis through two ITIM-independent signaling pathways (5, 6) .
Recent data suggest that the aberrant expression and function of CD32B on B cells is important in the pathogenesis of various autoimmune diseases (7, 8) . Specifically, CD32B gene deficiency increases both the susceptibility to autoimmunity and disease severity in mice (9) (10) (11) . In humans, decreased CD32B expression on B cells has been observed in patients with Ab-dependent autoimmune diseases, such as systemic lupus erythematosus (SLE), RA and chronic inflammatory demyelinating polyneuropathy (CIDP) (12) (13) (14) (15) (16) . The precise population of B cells that are affected by CD32B downregulation is disease specific. For example, whereas CD27 + memory B cells have decreased CD32B expression in SLE and RA, patients with chronic inflammatory demyelinating polyneuropathy show consistently lower levels of CD32B on both naive and memory B cells. Furthermore, in FcgRIIb transgenic mouse models, animals with increased CD32B expression on B cells experience early resolution of collagen-induced arthritis and SLE, whereas similar increases of CD32B on macrophages do not affect the course of these diseases (17 
2 ) and double-negative memory (CD27 2 IgD 2 ) subsets based on expression of the surface markers IgD and CD27 (18) . Alterations in the frequency and activation status of specific subsets of circulating B cells have been observed in various autoimmune diseases and are associated with disease duration, disease activity, and production of disease-specific autoantibodies (19) (20) (21) (22) . Despite the knowledge that B cell expression of CD32B is downregulated in patients with select autoimmune diseases, it is uncertain whether this reduced expression is restricted to specific B cell subsets. Furthermore, the mechanisms that regulate B cell-associated CD32B expression in RA are unknown.
In this report, we show that the CD27 + IgD 2 memory B cell population expresses significantly lower levels of CD32B in patients with active RA. Furthermore, we found that downregulation of CD32B on CD27 + IgD 2 B cells ex vivo is associated with upregulation of CD40L on CD4 T cells in RA patients. The physiologic relevance of CD40 in regulating CD32B expression is supported by data showing that CD40 ligation induces sustained reduction of CD32B expression on B cells. These findings suggest an important role of the CD40L-CD40 pathway in protecting B cells from FcgR checkpoint inhibition, and they define a potential treatment approach to restore B cell homeostasis in RA. 
Materials and Methods

Patients and controls
Cell preparation and activation
PBMCs were isolated from whole blood or buffy coat with Ficoll density gradient centrifugation (Amersham Biosciences). B lymphocytes were purified from PBMCs by negative selection using B cell isolation kit II (Miltenyi Biotec, Auburn, CA) according to the manufacturer's instructions. Purity of cell separations was typically .98%. All in vitro cell cultures were performed in RPMI 1640 (Mediatech) supplemented with 10% FCS (Atlanta Biologicals), 1% penicillin/streptomycin, 1% HEPES, and 1% Glutamax (all from Life Technologies). PBMCs or purified B cells were cultured at a concentration of 1 3 10 6 cells/ml in 96-well flat-bottom plates. To activate B cells, the following reagents were added at the initiation of culture: 10 mg/ml a-Igs F(ab9) 2 fragments (goat a-human IgA+IgG+IgM [H+L], Jackson ImmunoResearch), 1 mg/ml purified goat a-human CD40 Ab (R&D Systems), 5 mg/ml recombinant human CD40L (R&D Systems), 2.5 mg/ml CpG (InvivoGen). The following human recombinant cytokines were used to evaluate their effect on CD32B expression: 100 U/ml IL-2 (Proleukine, Chiron, Emeryville, CA), 20 ng/ml IL-4 (R&D Systems), 1 ng/ml IL-6 (BD Biosciences), 50 ng/ml IL-10 (eBioscience, San Diego, CA), 100 ng/ml IL-21 (BioSource International, Camarillo, CA), 20 ng/ml BAFF (eBioscience), 500 U/ml IFN-g (eBioscience), and 50 ng/ml TNF-a (BD Biosciences). To induce CD40L expression on T cells, PBMCs were activated with 5 mg/ml PWM (Sigma-Aldrich). Purified mouse a-human CD40L (20 mg/ml; BD Biosciences) mAb was used to block CD40-CD40L interactions.
Following informed consent, tonsils were obtained from patients undergoing routine tonsillectomies at the University of Maryland Medical Center. Cells were mechanically homogenized in complete medium and mashed through a 40-mm sieve to clear the cell solution from tissue fragments and cell clusters. The mononuclear cells were isolated by FicollPaque density centrifugation.
Flow cytometric analysis
For phenotypic analysis ex vivo, 100 ml whole blood was incubated with various combinations of conjugated mAbs to cell surface markers for 30 min at room temperature. RBCs were subsequently lysed in RBC lysis buffer (eBioscience) and washed twice with FACS buffer (0.5% BSA in PBS). For in vitro analysis of B cell phenotypes, cells were collected from cell culture, stained with indicated mAbs in FACS buffer, and washed twice. Labeled cells were acquired on an LSRII flow cytometer and analyzed with FACSDiva (BD Bioscience) or FlowJo software. The following mAbs were purchased from eBioscience: a-CD3 APC, CD27 PerCP-Cy5.5, PE conjugated a-CD23, CD38, CD80, CD95, CD154, BR3, TACI, and FITC-conjugated CD20. a-CD4 and IgD FITC, PE-conjugated a-CD11c, CD32, CD69, CD86, and isotype controls mouse IgG1 and Rat IgG2a were purchased from BD biosciences. PE-Cy7 and allophycocyaninlabeled a-CD19 mAbs and allophycocyanin-labeled CD32 mAb were purchased from BioLegend. For analysis, the lymphocyte population was gated based on forward and side scatter. Human peripheral blood B cells were defined using the CD19 + CD3 2 gate. For measurement of B cell activation and differentiation-associated markers, the percent of background staining with isotype controls was subtracted. B cell apoptosis was determined by staining with annexin V/7-aminoactinomycin D (Annexin V-PE Apoptosis Detection Kit I, BD Biosciences) according to the manufacturer's instructions.
Measurement of serum autoantibodies
Patients' plasma samples were collected after centrifuge separation of whole blood in an ACD-A BD Vacutainer and frozen at 280˚C. The levels of rheumatoid factor (RF) IgG (Orgentec Diagostika, Mainz, Germany) and a-CCP3.1 IgG/IgA (Inova Diagnostics, San Diego, CA) were measured with ELISA following the manufacturer's instructions. The cutoff level for both RF IgG and a-CCP3.1 IgG/IgA is 20 U/ml. Greater than 60 U/ml for a-CCP3.1 is considered strongly positive.
Quantitative RT-PCR
Total RNA was isolated using the SV Total RNA Isolation System (Promega), and cDNA was synthesized using the Maxima First Strand cDNA synthesis kit (Fermentas Life Sciences). Real-time quantitative PCR was performed using 7500-Fast Real-Time PCR Systems (Applied Biosystems, Foster City, CA) with specific primers, probes, and software (Applied Biosystems). The level of CD32b mRNA was quantified based on a titrated standard curve co-run in the same experiment and calibrated with the expression level of acidic ribosomal protein 36B4. All samples were done in triplicate.
Statistical analysis
Differences between defined patient and control groups were compared using the two-tailed nonparametric Mann-Whitney U test. Correlation was examined using Spearman rank correlation analysis; p , 0.05 is considered statistically significant. Data were analyzed using GraphPad Prism software (GraphPad Software).
Results
Peripheral B cell subsets are altered in patients with RA
We first determined the frequency of distinct B cell subsets, defined by the expression of CD27 and IgD, in the peripheral blood of healthy controls and patients with RA ( Fig. 1 Expression of CD32B is reduced on CD27 + IgD -memory B cells in patients with active RA and is associated with high levels of autoantibody production CD32B expression on circulating B cells is downregulated in several autoimmune diseases. For example, CD27 positive memory B cells have decreased CD32B expression in patients with RA (14) . Despite this knowledge, it is unclear whether this downregulation is restricted to specific memory B cell subsets or select populations within these subsets. To address these questions, we first compared the expression pattern of CD32B on specific B cell subsets from healthy donors. In contrast to the uniform expression of CD32B on IgD + B cells (both CD27 Fig. 2 ). This effect was enhanced when B cells were stimulated concurrently with a-Ig or CpG. In contrast, CpG stimulation did not induce the downregulation of CD32B, whereas a-Ig led to a slight reduction (Fig. 5A) . Next, we used recombinant CD40L, which lacks an Fc domain, to activate B cells in the presence of BCR crosslinking. Like a-CD40, CD40L stimulation mediated downregulation of CD32 on a-Ig activated B cells (Fig. 5B) . Furthermore, the addition of a-CD40L blocking mAb to PWM activated PBMCs, partially reversed these effects, indicating that the reduction of CD32B expression can occur as a result of naturally occurring CD40L-CD40 interactions (Fig. 5C ).
In keeping with these observations, a-CD40 stimulation decreased CD32b mRNA expression (Fig. 5D ).
To understand whether the observed loss of CD32B could be attributed to selective activation induced apoptosis of the CD32B high population, we cultured B cells in the presence of a-CD40 and studied the survival of CD32B low/neg and CD32B high subsets. Our data demonstrate that, following exposure to a-Ig a-CD40, both CD32B low/neg and CD32B high B cells have similar rates of apoptosis (data not shown). Importantly, this response appears to be durable, as prolonged exposure of B cells to a-CD40, results in sustained decreases in the levels of CD32B expression (Fig. 5E) .
Collectively, these data demonstrate that CD40 ligation induces persistent downregulation of CD32B expression on B cells and that this response is not simply a result of deleting the CD32B high B cell subset. 
CD40-mediated suppression of CD32B is potentiated by IL-4 and reversed by IL-21 and IL-10
Recent evidence suggests that binding of the soluble Fc component of i.v. Ig to DC-SIGN leads to upregulation of CD32B on regulatory macrophages in an IL-33-and IL-4-dependent fashion (26) . Based on these data, we sought to determine whether specific cytokines could work in concert with a-CD40 to modulate B cell expression of CD32B. In our initial studies, we screened a panel of cytokines known to modulate B cell activation or function (Fig. 6A) . When used in combination with a-Ig, a-CD40, or a-Ig/ a-CD40, IL-4 further reduced the expression of CD32B, whereas IL-21 induced CD32B upregulation. Interestingly, IL-6 and IL-10 also upregulated CD32B expression, but only in the presence of both a-Ig and a-CD40 stimulation. Importantly, whereas CD40 Correlation between CD32B downregulation on CD27 + IgD
2
B cells and CD40L T cells in patients with RA
Having demonstrated that CD40 signaling mediated CD32B downregulation on B cells from healthy donors in vitro, we next sought to understand the role of CD40/CD40L interactions in regulating in patients with RA. We first compared CD40L expression on resting and activated CD4 T cells between patients with RA and healthy controls, and we confirmed previously reported significant increases in CD40L expression in RA patients (Fig. 7A, 7B ) (27) . Furthermore, we found a significant correlation between CD4 T cell expression of CD40L and the size of the CD32B low/neg subpopulation in CD27 + IgD 2 B cells in RA (Fig. 7C) . These data provide indirect evidence that the high levels of CD40L found in patients with RA might contribute to the reduced levels of CD32B on select B cell subsets.
Discussion
In with enhanced B cell activation and autoantibody production. Whereas these changes in the absolute percentage of B cell expression of CD32B are relatively small, murine studies demonstrate that even small differences in B cell expression of CD32B have profound biologic significance (17) , and they suggest that our findings are physiologically relevant. Importantly, whereas phenotypic decreases in CD32B might be confounded by RF-or a-CCP-containing immune complexes interference with a-CD32B staining, these factors cannot completely account for our observations. Specifically, in vitro preincubation of B cells in serum with different levels of autoantibodies does not result in differential binding of detecting a-CD32B Ab on the B cell surface. (Supplemental Fig. 3 ) Furthermore, our data demonstrate that, in patients with high levels of RF and/or a-CCP, the levels of CD32B low/neg cells were selectively increased in the CD27 + IgD 2 subset, but not in the CD27 2 IgD 2 population. In addition, both CD27 + IgD + memory and CD27 2 IgD + naive B subsets from patients with RA express CD32B at similar levels as healthy controls (data not shown). If steric hindrance were artificially inhibiting a-CD32B staining, we would expect that these three B cell subsets would exhibit changes in CD32B expression analogous to those observed in the CD27 + IgD 2 B subset in patients with high levels of autoantibodies. In addition to RA, the dysregulation of CD32B on B cells has been reported in several other autoimmune diseases (13) (14) (15) . However, the mechanisms responsible for the B cell-specific downregulation of CD32B are uncertain. Based on the fact that (1) in vitro cell activation has been linked to the downregulation of CD32B on B cells (28) and (2) B cells in autoimmune diseases are in an abnormal state of activation (14, 29), we compared the role of different activation signals in regulating B cell-associated CD32B expression. In keeping with previous reports (28), CD40 stimulation alone causes significant downregulation of CD32B expression on B cells from healthy donors. Furthermore, although TLR stimulation alone has no effect and BCR crosslinking only induces an intermediate level of CD32B loss, the combination of CD40 costimulation with these signals produces synergistic downregulation of B cell-associated CD32B.
Compared with naive B cells, CD27 + IgD 2 memory B cells from both healthy donors and RA patients had an activated phenotype (Supplemental Fig. 1 ), as evidenced by enhanced expression of CD86, CD80, and CD95. Interestingly, there was no correlation between CD27 + IgD 2 memory B cell expression of CD32B and cell surface expression of CD80 and CD86 in healthy donors. In contrast, the frequency of CD32B low/neg in CD27 + IgD 2 memory B cells from patients with RA was strongly correlated with phenotypic and functional activation parameters. Considering that different B cell activation signals lead to different levels and different subset specific regulation of CD32B expression, we postulate that the mechanisms that induce B cell activation differ between patients with RA and healthy individuals. was analyzed using Spearman rank correlation analysis.
CD40-CD40L engagement plays a pivotal role in the pathogenesis of autoimmune diseases (30) . CD40L is expressed mainly on activated CD4 + T cells. In concordance with previous reports (27) , we observed that expression of CD40L is increased on both resting and activated CD4 + T cells in patients with RA. This increase might reflect an augmented and prolonged Ag driven activation of lymphocytes in patients. Alternatively, a recent study revealed that increased CD40L mRNA expression is associated with DNA demethylation in female patients with RA (31). Importantly, a significant correlation was noted between CD4 (34) . Therefore, our studies suggest that following CD40 ligation, these therapies could paradoxically enhance the ability of B cells to survive by limiting the effects of Ab-Ag-mediated signaling through CD32B. Our study is limited by the lack of information regarding CD32B expression on specific B cell subsets in diseased synovium. To gain insight into whether the observed downregulation of CD32B in specific B cell subsets is relevant to synovitis in RA, we analyzed the phenotype of GC B cells from tonsils with chronic inflammation. Our rationale for analyzing tonsillar tissue was that synovial tissue from patients with active RA forms ectopic lymphoid microstructures that are similar to those found in secondary lymphoid organs such as human tonsils (25) . Our data demonstrate that IgD 2 CD38 + GC B cells express low levels of CD32B and high levels of activation markers. The relevance of these findings is supported by a recent study (35) (36) . Our human B cell data, when taken in context with published findings in mice, suggest that the regulation of CD32B expression is also different between human and mouse B cells. For example, mouse B cells are reported to upregulate CD32B in response to LPS or a-BCR stimulation, whereas CD40 stimulation alone does not influence CD32B expression (32, 37) . In contrast, expression of CD32B on human B cells is downregulated in the presence of either CD40 stimulation or BCR crosslinking, but is not influenced by CpG stimulation. In vitro, IL-4 reduces CD32B expression on activated B cell from both human and mouse. Furthermore, although CD32B is upregulated on GC B cells in normal mice (38) , our study confirmed that it is downregulated on human GC B cells (39) . Considering the essential role of CD40:CD40L interactions in the GC response, we postulate that the differential regulation of CD32B expression induced by CD40 stimulation of human and mouse B cells, might contribute to the observed disparity in CD32B expression on GC B cells between humans and mice in vivo.
Genetic variants of CD32B gene are reported to affect the expression and function of this receptor and be associated with select autoimmune conditions in both mice and humans (40) (41) (42) . We cannot completely exclude the possibility that specific CD32B polymorphisms, known to affect CD32B expression, partially account for our observations in RA; however, the extremely low prevalence of these polymorphisms limits their potential influence on our findings (41, 42) .
In summary, we identified a subpopulation of CD32 low/neg B cells in the CD27 + IgD 2 memory B cell subset in patients with RA, which is associated with disease activity and autoantibody production. This CD32B downregulation is mediated by CD40-CD40L interactions and is secondarily regulated by the cytokine milieu. Understanding of these regulatory pathways provides potential sites, alone and in combination, for therapeutic intervention in autoimmune disease. 
